Biotechnology company VistaGen Therapeutics is putting humans first with Human Clinical Trials in a Test Tube. This human pluripotent stem cell (hPSC) technology platform has been developed to provide clinically relevant predictions of potential toxicity long before drug candidates are … Continue reading →

VistaGen Therapeutics employs the expertise of company co-founder and renowned Canadian stem cell scientist Dr. Gordon Keller, as well as co-founder, president, and chief scientific officer Dr. Ralph Snodgrass. Human Clinical Trials in a Test Tube™, the company’s human pluripotent … Continue reading →

Antidepressants are the most commonly consumed class of therapeutics in the United States, prescribed to more than 270 million patients each year. Ketamine, an NMDA receptor antagonist used as an anesthetic in human and veterinary medicine, can also be effective … Continue reading →

VistaGen is a biotech company applying its human pluripotent stem cell (hPSC) technology for drug rescue, including predictive toxicology and drug metabolism screening. The company’s human pluripotent stem cell (hPSC) technology platform, Human Clinical Trials in a Test Tube™, is … Continue reading →

With grant funding from the U.S. National Institutes of Health (NIH), biotechnology company VistaGen Therapeutics, Inc. has successfully completed Phase 1 development of AV-101, an orally available small molecule prodrug candidate. AV-101 is targeted at the multibillion-dollar neurological disease and … Continue reading →

VistaGen Therapeutics, a biotechnology company, is blazing new trails by looking to the past. The company has developed a pioneering stem cell technology platform that can give a second chance to potentially lifesaving drugs that have been shelved during human … Continue reading →

VistaGen Therapeutics has developed a versatile human pluripotent stem cell (hPSC) technology platform based on the controlled differentiation of hPSCs into mature, non-transformed, human cells. The company’s goal is to integrate this hPSC technology with modern medicinal chemistry to create … Continue reading →

The limitations of current animal and in vitro cell culture testing have long been a stumbling block for pharmaceutical companies as they endeavor to develop new lifesaving drugs. A drug candidate that has shown great promise in preclinical development can … Continue reading →

Approximately one-third of all potential new drug candidates are shelved in their late-stage development due to preclinical or clinical safety concerns. As a result, in the last decade the number of new drugs that are approved each year has dramatically … Continue reading →

VistaGen Therapeutics has developed a unique stem cell technology platform called Human Clinical Trials in a Test Tube™ – it’s a fairly simple name representing a complex and innovative bioassay system with the ability to predict potential toxicity and metabolism … Continue reading →